Complimentary Commercial Content
Zoetis has announced the recent U.S. commercial launches of Librela™ (bedinvetmab injection) and Apoquel® Chewable (oclacitinib chewable tablet). The products are the first and only FDA-approved treatment formulations in their respective categories and address individualized care and health needs of dogs with specific and diverse lifestyles.
- Librela is a once-a-month injectable anti-NGF monoclonal antibody treatment to control canine osteoarthritis pain
- Apoquel Chewable is a chewable treatment for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs
Source: Zoetis press release, October 9, 2023. Link.
